SVF Vaccines Reports Promising Preclinical Results for SVF-001 Immunotherapy in Chronic Hepatitis B and D Coinfection
Key Insights
SVF Vaccines (search) presented positive preclinical data for SVF-001, a DNA-based immunotherapy targeting chronic hepatitis B (search) and D coinfection, at major scientific conferences in Berlin and Hannover.
The preclinical study demonstrated significant antiviral effects in a humanized-liver mouse model, with deep reductions in both hepatitis B virus DNA and hepatitis D virus (search) RNA levels in blood following SVF-001 administration.
The therapeutic candidate represents part of SVF Vaccines (search)' next-generation vaccine platform that aims to both prevent disease and cure infected patients with chronic viral hepatitis.
SVF Vaccines (search), a portfolio company of Karolinska Development AB (search), has reported encouraging preclinical results for its immunotherapy candidate SVF-001 in treating chronic hepatitis B (search) and D coinfection. The data were presented at two prominent scientific meetings: the Molecular Biology of HBV meeting in Berlin in September and the DeltaCure meeting in Hannover in October 2025.
Preclinical Study Results
The preclinical study evaluated SVF-001's therapeutic potential using a humanized-liver mouse model of chronic HBV/HDV coinfection (search). Administration of the DNA-based immunotherapy resulted in deep reductions of both hepatitis B virus DNA and hepatitis D virus (search) RNA levels in blood, demonstrating significant antiviral activity against both pathogens.
The study findings support the therapeutic approach of targeting dual viral infections, which represents a significant clinical challenge as hepatitis D virus (search) requires hepatitis B virus for its replication and pathogenesis.
Technology Platform and Development Strategy
SVF Vaccines (search) develops DNA vaccines and immunotherapies based on proprietary technology originating from Karolinska Institutet. The company's approach focuses on creating therapeutic and prophylactic vaccines designed to both prevent disease and potentially cure infected patients.
"SVF Vaccines (search) is developing the next generation of therapeutic and prophylactic vaccines that potentially can both prevent disease and cure infected patients. The recently presented results are promising and support the therapeutic potential for SVF-001 in patients coinfected with chronic hepatitis B (search) and D," stated Viktor Drvota, CEO of Karolinska Development.
Pipeline and Corporate Structure
Beyond SVF-001, SVF Vaccines (search) maintains a portfolio that includes early-stage discovery programs targeting other serious infectious diseases. The company operates as part of Karolinska Development's investment strategy, with the parent company holding a 33 percent ownership stake in SVF Vaccines.
Karolinska Development AB (search), listed on Nasdaq Stockholm under the ticker KDEV, functions as a Nordic life sciences investment company that identifies breakthrough medical innovations in the Nordic region. The company leverages access to world-class medical innovations at Karolinska Institutet and other leading universities and research institutes across the Nordic region.